This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Don't Lose Confidence, Scoop Up These 5 Retail Stocks Instead
by Sumit Singh
Consumer confidence declined for the second successive month in December. But these retailers - DICK'S Sporting (DKS), Beacon Roofing Supply (BECN), MarineMax (HZO), Rite Aid (RAD) Target (TGT) - could still be a great addition to your portfolio.
DICK'S Sporting (DKS) Steps Up Delivery Via Instacart Partnership
by Zacks Equity Research
DICK'S Sporting (DKS) launches same-day delivery services in more than 150 stores via Instacart. This move will help reap benefits of the coronavirus-led online boom.
Rite Aid (RAD) Soars on Earnings & Revenues Beat in Q3
by Zacks Equity Research
Rite Aid's (RAD) Q3 results gain from solid demand, rise in same-store prescription count, strength in Elixir brand and robust online growth. Also, it is progressing well with RxEvolution strategy.
Rite Aid (RAD) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Rite Aid (RAD) delivered earnings and revenue surprises of 4100.00% and 4.63%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?
Things You Must Know Ahead of Rite Aid's (RAD) Q3 Earnings
by Zacks Equity Research
Strong performance in the retail pharmacy and pharmacy services segments is likely to have aided Rite Aid's (RAD) Q3 revenues. Also, solid demand for essentials has been driving performance.
Earnings Preview: Rite Aid (RAD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Rite Aid (RAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rite Aid (RAD) Catches Eye: Stock Jumps 7.6%
by Zacks Equity Research
Rite Aid (RAD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Amazon (AMZN) Ups Pharmacy Retail Game With New Online Store
by Zacks Equity Research
Amazon (AMZN) unveils Amazon Pharmacy, the new online store for prescription medicines. This is likely to drive its customer momentum amid the pandemic.
Zacks Industry Outlook Highlights: CVS, Walgreens Boots, Rite Aid, Amazon and Herbalife
by Zacks Equity Research
Zacks Industry Outlook Highlights: CVS, Walgreens Boots, Rite Aid, Amazon and Herbalife
2 Top Retail Pharmacy and Drug Store Stocks to Beat Volatility
by Urmimala Biswas
Social-distancing measures to combat coronavirus have dented demand for Retail Pharmacy and Drug Store industry, casting a shadow on its outlook. Industry participants like CVS and HLF however seem to be in a position to tide over the situation.
5 Toxic Stocks That You Should Not be Owning
by Rimmi Singhi
Figuring out bloated toxic stocks on a consistent basis and discarding them at the right time is the key to successful investing.
Rite Aid Ups Game in PBM Space Via Bartell Drugs' Buyout
by Zacks Equity Research
Rite Aid's (RAD) acquisition deal with Bartell Drugs is likely to strengthen its foothold in mid-market PBM and help boost the RxEvolution strategy.
Do Options Traders Know Something About Rite Aid (RAD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Rite Aid (RAD) stock based on the movements in the options market lately.
Rite Aid (RAD) Surpasses Earnings & Sales Estimates in Q2
by Zacks Equity Research
Rite Aid's (RAD) Q2 results gain from solid demand, rise in same-store prescription count, strength in Elixir brand and cost-cutting plans.
Rite Aid (RAD) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Rite Aid (RAD) delivered earnings and revenue surprises of 127.27% and 3.92%, respectively, for the quarter ended August 2020. Do the numbers hold clues to what lies ahead for the stock?
Rite Aid (RAD) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Rite Aid's (RAD) Q2 results are likely to reflect gains from enhanced digital capabilities to provide essential services, sturdy Elixir performance and solid growth in prescription deliveries.
Earnings Preview: Rite Aid (RAD) Q2 Earnings Expected to Decline
by Zacks Equity Research
Rite Aid (RAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rite Aid (RAD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Rite Aid (RAD) closed the most recent trading day at $15.16, moving -0.52% from the previous trading session.
Rite Aid Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Rite Aid has been struggling lately, but the selling pressure may be coming to an end soon.
Rite Aid (RAD) Down 7.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Rite Aid (RAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Rite Aid Continues Expansion of Coronavirus Testing Sites
by Zacks Equity Research
Rite Aid (RAD) is aggressively expanding COVID-19 testing locations by adding 161 more sites in order to curb the effects of coronavirus.
The Zacks Analyst Blog Highlights: Nautilus, Rite Aid, EXFO, MarineMax and Strattec Security
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Nautilus, Rite Aid, EXFO, MarineMax and Strattec Security
Small Business Optimism Rises Amid Coronavirus Woes: 5 Picks
by Nalak Das
We have narrowed down our search to five small-cap stocks that have popped more than 10% in the past month with strong growth potential.
Top Ranked Momentum Stocks to Buy for July 15th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 15th
Top Ranked Momentum Stocks to Buy for July 13th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 13th